Jennifer Frausto
Psychiatric/Mental Health · Casper, WYNPI 1205268513
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 517 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lundbeck LLC$918
- Teva Pharmaceuticals USA, Inc.$752
- Otsuka America Pharmaceutical, Inc.$714
- Ironshore Pharmaceuticals Inc.$593
- Alkermes, Inc.$572
- plus $3K from 15 others
What the payments were for
- Food & beverage$7,30395%
- Education$3765%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $1,098 |
| Lundbeck LLC | 56 | $918 |
| Teva Pharmaceuticals USA, Inc. | 34 | $752 |
| Otsuka America Pharmaceutical, Inc. | 47 | $714 |
| Ironshore Pharmaceuticals Inc. | 40 | $593 |
| Alkermes, Inc. | 45 | $572 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $457 |
| Supernus Pharmaceuticals, Inc. | 28 | $445 |
| Vanda Pharmaceuticals Inc. | 41 | $409 |
| Neurocrine Biosciences, Inc. | 17 | $344 |
| Sunovion Pharmaceuticals Inc. | 25 | $338 |
| Corium, LLC | 23 | $320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $225 |
| Idorsia Pharmaceuticals US Inc | 8 | $138 |
| Collegium Pharmaceutical, Inc. | 5 | $100 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| Eisai Inc. | 4 | $60 |
| Merck | 3 | $55 |
| Johnson & Johnson | 2 | $33 |
| OWP Pharmaceuticals, Inc. | 1 | $18 |
| Cognoa, Inc. | 1 | $17 |
How this compares
$7,680 in reported general payments places this provider in the 95th percentile of 76 psychiatric/mental health providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 40 | $141,919 |
| IngrezzaValbenazine Tosylate | 12 | $110,176 |
| RexultiBrexpiprazole | 62 | $110,049 |
| FanaptIloperidone | 32 | $84,765 |
| Abilify MaintenaAripiprazole | 16 | $44,914 |
| VraylarCariprazine Hcl | 22 | $44,708 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $34,151 |
| BelsomraSuvorexant | 64 | $29,942 |
| AustedoDeutetrabenazine | 12 | $29,913 |
| TrintellixVortioxetine Hydrobromide | 39 | $28,363 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $19,931 |
| Lurasidone Hcl | 63 | $13,279 |
| Atomoxetine Hcl | 108 | $12,685 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 25 | $9,066 |
| Aripiprazole | 202 | $5,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $714 | $154,96278 claims |
| Johnson & JohnsonInvega Sustenna | $33 | $141,91940 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $344 | $110,17612 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $409 | $84,76532 claims |
| AbbVieVraylar, Viibryd | $1,098 | $49,49136 claims |
| Alkermes, Inc.Lybalvi | $572 | $34,15120 claims |
| MerckBelsomra | $55 | $29,94264 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $752 | $29,91312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $225 | $28,36339 claims |
| Axsome Therapeutics, Inc.Auvelity | $75 | $19,93118 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $593 | $5,16211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 76 psychiatric/mental health providers in Wyoming.
Other psychiatric/mental health in Casper
- Michelle HipsakCasper$6K
- Rebekah LayherCasper$4K
- Teecee Hailey-FulferCasper$4K
- Jayme DonaldsonCasper$3K
- Karen GravesCasper$3K
- Sarah BurtCasper$3K
- Carla PootCasper$2K
- Crystal BardgettCasper$2K
- McKenzie FrederickCasper$1K
- Donna NurssCasper$975
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.